Accessibility Menu
Autolus Therapeutics Plc logo

Autolus Therapeutics Plc(NASDAQ) AUTL

Market Cap$561.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-92%
5 Year-65%
1 Year-10%
1 Month+24%
$2.12
+6.00%
+0.12Today
After hours$2.11-$0.01 (-0.47%)
Autolus Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 2.112026-08-07
Autolus Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+41.61%USD 1.492026-07-31
1 month+24.12%USD 1.702026-07-08
3 month+34.39%USD 1.572026-05-08
Year to date+6.03%USD 1.992025-12-31
1 year-10.21%USD 2.352025-08-07
3 year-28.96%USD 2.972023-08-08
5 year-65.24%USD 6.072021-08-06
Since inception-91.56%USD 25.002018-06-22

Autolus Therapeutics Plc Financials at a Glance

Market Cap

$561.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$92.59M

Net Income (TTM)

-$288.83M

EPS (TTM)

-$1.09

P/E Ratio

-1.94

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$2.12

Volume

2,035,646.526

Open

$2.04

Previous Close

$2.11

Daily Range

$2.03 - $2.13

52-Week Range

$1.18 - $2.52

Estimated Earnings Date

Aug 11, 2026

AUTL News

Scientists in a lab, monitor, microscope

Why Autolus Therapeutics Stock Is Crashing Today

Keith SpeightsDec 9, 2022
Handshake - GettyImages-1215758851

Why Autolus Therapeutics Stock Jumped 25% Today

Joe TenebrusoNov 8, 2021
scientist-working-under-fume-hood

Here's Why Autolus Therapeutics Is Surging Today

Cory RenauerAug 2, 2021
Scientist looking through a microscope

Why Autolus Therapeutics Stock Skyrocketed Today

Keith SpeightsMay 12, 2021
Test tubes with DNA helix

Why Autolus Therapeutics Shares Are Plunging Today

Keith SpeightsJan 23, 2020
Stethascope

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

David HaenOct 9, 2019

AUTL: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Autolus Therapeutics Plc

Autolus makes custom treatments to help the body fight cancer. These therapies reprogram a person's own cells to attack sick cells. This helps adults and children with serious blood diseases or lupus.

Fighting Cancer With Better Cells

  • AUCATZYL (obe-cel): Personalized therapy for adults with a fast-growing blood cancer called acute lymphoblastic leukemia; manufactured at the company's dedicated site in the United Kingdom.
  • Pediatric Programs: Investigational therapies like obe-cel and AUTO1/22 for children with relapsed blood cancers; designed to address diseases that return after initial treatment.
  • Autoimmune Treatments: Clinical trials using obe-cel to treat chronic conditions like lupus and multiple sclerosis; based on resetting the immune system by removing specific faulty cells.
  • Pipeline Candidates: Early-stage programs targeting different types of lymphoma and solid tumors; uses modular technology to customize how the therapy recognizes and kills targets.

Building for the Future

  • Launched AUCATZYL in the United States in January 2025 following approval from the FDA.
  • Introduced the therapy in the United Kingdom in January 2026 after receiving conditional marketing authorization and recommendation from health authorities.
  • Partnered with BioNTech to collaborate on research, development, and commercialization of new product candidates.
  • Opened the Nucleus, a dedicated 70,000 square foot manufacturing facility in Stevenage, United Kingdom, to control global supply.
  • Secured FDA regenerative medicine advanced therapy designation for treating children with blood cancer in October 2025.

What Makes the Tech Different?

Autolus uses a unique "fast off-rate" design that lets therapy cells kill targets and move on quickly to reduce side effects. The company also controls its own specialized manufacturing center to ensure quality and supply for its personalized medicine.

Tracking the Latest Numbers

  • Revenue reached $24.3 million in Q4 2025, up from $29,000 in Q4 2024.
  • Gross profit was -$1 million in Q4 2025, which improved from -$138.3 million in Q4 2024.
  • Operating income was -$72.4 million in Q4 2025, improved from -$241.4 million in Q4 2024.
  • Net income was -$90.2 million in Q4 2025, worsened from -$27.6 million in Q4 2024.
  • Free cash flow was -$91.1 million in Q4 2025, worsened from -$61.8 million in Q4 2024.

Moving From Lab to Market

Autolus has transitioned from a research company to a commercial business with the launch of its first approved blood cancer therapy. It is now expanding its technology to treat autoimmune diseases like lupus and multiple sclerosis.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

752

CEO

Christian Martin Itin, PhD

Website

www.autolus.com

Headquarters

London, GL W12 7FP, GB

AUTL Financials

Key Financial Metrics (TTM)

Gross Margin

-11.19%

Operating Margin

-285.90%

Net Income Margin

-311.95%

Return on Equity

-128.53%

Return on Capital

-53.13%

Return on Assets

-54.80%

Earnings Yield

-51.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$561.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

266.16M

Volume

2.04M

Avg. Volume

1.60M

Financials (TTM)

Gross Profit

-$10.36M

Operating Income

-$264.71M

EBITDA

-$230.80M

Operating Cash Flow

-$273.32M

Capital Expenditure

-$18.20M

Free Cash Flow

-$291.52M

Cash & ST Invst.

$229.43M

Total Debt

$79.96M

Autolus Therapeutics Plc Performance Analysis

Autolus Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 6,190,177310.8%
20232023-12-31USD 1,704,582-72.5%
20242024-12-31USD 10,124,258493.9%
20252025-12-31USD 75,564,172646.4%
Autolus Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30132.9%
Q32025-09-301.3%
Q42025-12-3114.4%
Q12026-03-318.1%
Autolus Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.57-20.6%
20232023-12-31USD -1.20-23.2%
20242024-12-31USD -0.87-28.1%
20252025-12-31USD -1.0825.2%
Autolus Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3030.8%
Q32025-09-30-66.7%
Q42025-12-31-13.3%
Q12026-03-3120.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$26.22M

+191.9%

Gross Profit

$1.65M

+118.4%

Gross Margin

6.29%

N/A

Market Cap

$561.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$746.79K

N/A

Employees

752

N/A

Net Income

-$71.60M

-2.0%

EBITDA

-$56.94M

-2.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$229.43M

-55.6%

Total Debt

$79.96M

-74.3%

Accounts Receivable

$86.26M

+502.5%

Inventory

$33.23M

+126.9%

Long Term Debt

$76.90M

-75.0%

Short Term Debt

$3.06M

+2.9%

Return on Assets

-54.80%

N/A

Return on Invested Capital

-57.12%

N/A

Free Cash Flow

-$68.00M

+18.9%

Operating Cash Flow

-$65.32M

+13.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BNTCBenitec Biopharma Inc.
$13.63+3.81%
RCKTRocket Pharmaceuticals, Inc.
$3.61+1.98%
NMRANeumora Therapeutics, Inc. Common Stock
$1.63-0.61%
SLDBSolid Biosciences Inc.
$8.39-3.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About AUTL

What is the current price of Autolus Therapeutics Plc?

Autolus Therapeutics Plc is trading at $2.11 per share.

What is the 52-week range for Autolus Therapeutics Plc?

Over the past 52 weeks, Autolus Therapeutics Plc has traded between $1.18 and $2.52.

How much debt does Autolus Therapeutics Plc have?

As of the most recent reporting period, Autolus Therapeutics Plc reported total debt of $369.12M.

How much cash does Autolus Therapeutics Plc have on hand?

Autolus Therapeutics Plc reported $132.42M in cash and cash equivalents in its most recent financial results.

What is Autolus Therapeutics Plc’s dividend yield?

Autolus Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services